Changing the paradigm of osteoarthritis treatment
OUR SOLUTION
Routine intra-articular injection procedure of a small-molecule drug into a joint cavity after traumatic injury to prevent osteoarthritis
First-mover that fulfills a major unmet medical need!
About CartilaGen
THE PROBLEM
-
Posttraumatic osteoarthritis (PTOA) is the number one disabling condition leading to medical discharge of wounded warriors from active duty
-
PTOA affects over six million civilians at a cost of nearly $15 billion annually to the United States
-
PTOA has devastating effects on patients and current treatment options are limited and ineffective before end-stage joint replacement
OUR VISION
-
Drug-eluting, bioactive hydrogel proven effective for PTOA prevention
-
Targets the earliest stage of PTOA development and treats the underlying disease mechanism in an easily performed, cost-effective manner
-
Designed for cartilage injuries and early stage osteoarthritis
-
Combined Phase I/IIa clinical trial scheduled
OUR PARTNERS
-
University of Iowa Hospitals and Clinics
-
Indiana University Health
-
US Department of Defense
-
METRC (Major Extremity Trauma and Rehabilitation Consortium)